KME 2780
Alternative Names: KME-2780Latest Information Update: 08 Feb 2023
Price :
$50 *
At a glance
- Originator Cincinnati Children's Hospital Medical Center; National Center for Advancing Translational Sciences
- Developer Kurome Therapeutics
- Class Antineoplastics
- Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 10 Dec 2022 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) before December 2022
- 10 Dec 2022 Preclinical trials in Myelodysplastic syndromes in USA (unspecified route) before December 2022